Ligand subsidiary Vernalis and PhoreMost announce drug discovery collaboration
Ligand and PhoreMost announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. Vernalis and PhoreMost will share downstream revenues of any future out-licenses. June 12, 2019